Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
grade F 4.075 3.69% 0.15
DVAX closed down 0.76 percent on Friday, October 11, 2019, on 37 percent of normal volume. It ran into resistance at its 50 day moving average.

Earnings due: Nov 4

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical DVAX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 3.69%
MACD Bullish Signal Line Cross Bullish 3.69%
Wide Bands Range Expansion 3.69%
Fell Below 50 DMA Bearish 2.90%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.90%
Narrow Range Bar Range Contraction 2.90%
NR7 Range Contraction 2.90%
Inside Day Range Contraction 2.90%
Wide Bands Range Expansion 2.90%
20 DMA Resistance Bearish 1.88%

Older signals for DVAX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Health Biopharmaceutical Pharmaceutical Industry Asthma Astrazeneca Autoimmune And Inflammatory Diseases Chronic Obstructive Pulmonary Disease Treatment Of Autoimmune And Inflammatory Diseases Novel Products Tlr7 Tlr9
Is DVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.75
52 Week Low 2.59
Average Volume 1,590,851
200-Day Moving Average 6.35
50-Day Moving Average 4.0195
20-Day Moving Average 4.0318
10-Day Moving Average 3.7355
Average True Range 0.2966
ADX 17.78
+DI 22.0972
-DI 19.5811
Chandelier Exit (Long, 3 ATRs ) 4.1702
Chandelier Exit (Short, 3 ATRs ) 4.1798
Upper Bollinger Band 4.8486
Lower Bollinger Band 3.215
Percent B (%b) 0.44
BandWidth 40.517883
MACD Line -0.0979
MACD Signal Line -0.0985
MACD Histogram 0.0006
Fundamentals Value
Market Cap 215.52 Million
Num Shares 54.8 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -1.62
Price-to-Sales 143.85
Price-to-Book 7.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.17
Resistance 3 (R3) 4.18 4.10 4.13
Resistance 2 (R2) 4.10 4.04 4.10 4.12
Resistance 1 (R1) 4.02 4.00 3.98 4.01 4.10
Pivot Point 3.94 3.94 3.93 3.94 3.94
Support 1 (S1) 3.86 3.88 3.82 3.85 3.76
Support 2 (S2) 3.78 3.84 3.78 3.74
Support 3 (S3) 3.70 3.78 3.73
Support 4 (S4) 3.69